851776-30-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclopentapyrazolecarboxamide, 1,4,5,6-tetrahydro-, is used as a potential pharmaceutical compound for its unique structural features, which may offer therapeutic benefits in the development of new drugs. Its cyclic amide and pyrazole-cyclopentane ring system could be leveraged to target specific biological pathways or receptors, contributing to the discovery of novel treatments for various diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Cyclopentapyrazolecarboxamide, 1,4,5,6-tetrahydro-, serves as a valuable intermediate for the synthesis of other complex organic molecules. Its unique structure can be further modified or functionalized to create a range of derivatives with diverse properties and applications, expanding the scope of chemical research and development.
Further research and analysis are required to determine the exact potential and applications of 3-Cyclopentapyrazolecarboxamide, 1,4,5,6-tetrahydro-, in various industries. Its unique structural features and potential reactivity may open up new avenues for innovation and advancement in pharmaceuticals, organic synthesis, and other related fields.

Upstream product

• 5932-31-0 1,2-diazabicyclo[3,3,0^4,8]octa-3,8-diene-3-carboxylic acid ethyl ester 
• 5932-32-1 1,4,5,6-tetrahydro-cyclopenta[c]pyrazole-3-carboxylic acid 

Downstream Products

• 851776-29-9 1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonitrile 
• 851776-32-4 1-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide 
• 851776-33-5 2-benzyl-2,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide 

Relevant academic research and scientific papers

Development of a scaleable synthesis of a partial nicotinic acid receptor agonist

A practical and efficient synthesis of 1,4,5,6-tetrahydro-3-(1Htetrazol- 5-yl)cyclopenta[c]pyrazole, 1, is described. A new one-pot process has been developed, starting from the commercially available 1H-tetrazole-5-carboxylic acid-ethyl ester sodium salt which is reacted in a pseudo-Claisen condensation reaction with cyclopentanone, followed by the addition of hydrazine.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice

The discovery and profiling of 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro- cyclopentapyrazole (5a, MK-0354), a partial agonist of GPR109a, is described. Compound 5a retained the plasma free fatty acid lowering effects in mice associated with GPR109a agonism,

COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS

The invention provides a method of reducing flushing induced by niacin or a niacin analog in a subject, comprising administering to said subject an effective flush reducing amount of a niacin receptor partial agonist. In addition, the invention provides a

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. T

TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF

The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present in